Zentalis Pharmaceuticals (NASDAQ:ZNTL) Issues Earnings Results, Misses Estimates By $0.10 EPS

Zentalis Pharmaceuticals (NASDAQ:ZNTL) announced its quarterly earnings data on Thursday. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.10), FiscalAI reports.

Zentalis Pharmaceuticals Stock Performance

Shares of NASDAQ:ZNTL opened at $5.00 on Friday. The stock has a market capitalization of $355.95 million, a price-to-earnings ratio of -2.89 and a beta of 1.92. The stock’s 50-day simple moving average is $4.31 and its two-hundred day simple moving average is $3.59. Zentalis Pharmaceuticals has a 52-week low of $1.21 and a 52-week high of $6.95.

Wall Street Analysts Forecast Growth

ZNTL has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research report on Monday, July 6th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday, May 22nd. Rodman & Renshaw initiated coverage on shares of Zentalis Pharmaceuticals in a report on Thursday, July 23rd. They set a “buy” rating and a $11.00 price target on the stock. Mizuho assumed coverage on shares of Zentalis Pharmaceuticals in a research report on Friday, July 17th. They set an “outperform” rating and a $8.00 price target for the company. Finally, Wall Street Zen upgraded shares of Zentalis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Sunday, May 31st. Four equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Zentalis Pharmaceuticals currently has an average rating of “Hold” and an average price target of $6.75.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several institutional investors have recently made changes to their positions in the business. Invesco Ltd. boosted its holdings in shares of Zentalis Pharmaceuticals by 8.6% in the fourth quarter. Invesco Ltd. now owns 188,582 shares of the company’s stock worth $255,000 after buying an additional 14,961 shares during the last quarter. XTX Topco Ltd increased its holdings in Zentalis Pharmaceuticals by 5.1% during the fourth quarter. XTX Topco Ltd now owns 576,707 shares of the company’s stock valued at $779,000 after buying an additional 28,078 shares during the last quarter. Quadrature Capital Ltd raised its position in Zentalis Pharmaceuticals by 126.8% in the fourth quarter. Quadrature Capital Ltd now owns 137,568 shares of the company’s stock worth $186,000 after acquiring an additional 76,917 shares during the period. Opaleye Management Inc. raised its position in Zentalis Pharmaceuticals by 342.6% in the fourth quarter. Opaleye Management Inc. now owns 1,400,906 shares of the company’s stock worth $1,891,000 after acquiring an additional 1,084,356 shares during the period. Finally, ADAR1 Capital Management LLC boosted its stake in shares of Zentalis Pharmaceuticals by 60.0% during the 4th quarter. ADAR1 Capital Management LLC now owns 80,000 shares of the company’s stock worth $108,000 after acquiring an additional 30,000 shares during the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.